BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23740007)

  • 1. Thermotherapy effective and safer than miltefosine in the treatment of cutaneous leishmaniasis in Colombia.
    López L; Cruz C; Godoy G; Robledo SM; Vélez ID
    Rev Inst Med Trop Sao Paulo; 2013; 55(3):. PubMed ID: 23740007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
    Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J
    Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
    López L; Robayo M; Vargas M; Vélez ID
    Trials; 2012 May; 13():58. PubMed ID: 22594858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Miltefosine for new world cutaneous leishmaniasis.
    Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
    Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran.
    Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A
    Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of thermotherapy to treat cutaneous leishmaniasis in Colombia: a comparative observational study in an operational setting.
    Vega JC; Sanchez BF; Montero LM; Montaña R; Mahecha Mdel P; Dueñes B; Baron AR; Reithinger R
    Trans R Soc Trop Med Hyg; 2009 Jul; 103(7):703-6. PubMed ID: 19059616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis.
    Vélez I; López L; Sánchez X; Mestra L; Rojas C; Rodríguez E
    Am J Trop Med Hyg; 2010 Aug; 83(2):351-6. PubMed ID: 20682881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Miltefosine: oral treatment of leishmaniasis.
    Soto J; Soto P
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):177-85. PubMed ID: 16597200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miltefosine in cutaneous leishmaniasis.
    Rahman SB; ul Bari A; Mumtaz N
    J Coll Physicians Surg Pak; 2007 Mar; 17(3):132-5. PubMed ID: 17374296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis.
    Cardona-Arias JA; López-Carvajal L; Tamayo Plata MP; Vélez ID
    J Evid Based Med; 2017 May; 10(2):81-90. PubMed ID: 28276641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of cutaneous leishmaniasis with thermotherapy in Brazil: an efficacy and safety study.
    Gonçalves SVCB; Costa CHN
    An Bras Dermatol; 2018 Jun; 93(3):347-355. PubMed ID: 29924242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oral miltefosine to treat leishmaniasis].
    Soto J; Soto P
    Biomedica; 2006 Oct; 26 Suppl 1():207-17. PubMed ID: 17361856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral miltefosine for Indian visceral leishmaniasis.
    Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
    N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of New World cutaneous leishmaniasis with miltefosine.
    Soto J; Berman J
    Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S34-40. PubMed ID: 16930649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
    Dorlo TP; Balasegaram M; Beijnen JH; de Vries PJ
    J Antimicrob Chemother; 2012 Nov; 67(11):2576-97. PubMed ID: 22833634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
    Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
    Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
    Sundar S; Singh A; Chakravarty J; Rai M
    ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment.
    Calvopina M; Gomez EA; Sindermann H; Cooper PJ; Hashiguchi Y
    Am J Trop Med Hyg; 2006 Dec; 75(6):1074-7. PubMed ID: 17172368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Miltefosine: a new remedy for leishmaniasis].
    Dorlo TP; Eggelte TA; Beijnen JH; de Vries PJ
    Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2697-701. PubMed ID: 17194005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.